v3.22.4
Collaborations (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
AbbVie's receivable from Janssen $ 11,254 $ 9,977  
AbbVie's payable to Janssen $ 25,402 22,699  
Collaborative arrangement      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Share of collaboration development costs responsible by the entity (as a percent) 40.00%    
Janssen Biotech, Inc | Collaborative arrangement      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Milestone payments $ 200    
Share of collaboration development costs responsible by Janssen (as a percent) 60.00%    
Global - AbbVie's share of other costs (included in respective line items) $ 268 304 $ 295
AbbVie's receivable from Janssen 295 294  
AbbVie's payable to Janssen 379 509  
Janssen Biotech, Inc | Collaborative arrangement | United States      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 1,607 2,018 2,012
Janssen Biotech, Inc | Collaborative arrangement | International      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
International - AbbVie's share of profits (included in net revenues) 1,142 1,087 1,009
Genentech, Inc. | Collaborative arrangement      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 778 703 533
AbbVie's share of development costs (included in R&D) 121 140 129
Genentech, Inc. | Collaborative arrangement | United States      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) $ 37 $ 40 $ 46